Open AccessPhase 1b safety study of farletuzumab, carboplatin and pegylated liposomal doxorubicin in patients with platinum-sensitive epithelial ovarian cancer
Author(s) -
Kenneth H. Kim,
Danijela Jelovac,
Deborah K. Armstrong,
Benjamin J. Schwartz,
Susan C. Weil,
Charles Schweizer,
Ronald D. Alvarez
Publication year - 2016
Publication title -
carolina digital repository (university of north carolina at chapel hill)
Language(s) - English
DOI - 10.17615/8wrf-r472
Subject(s) - carboplatin , ovarian cancer , doxorubicin , platinum , medicine , epithelial ovarian cancer , oncology , pharmacology , cancer research , cisplatin , cancer , chemotherapy , chemistry , biochemistry , catalysis